SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 273 filers reported holding SAGE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.75 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,726,134 | -90.1% | 181,056 | -77.3% | 0.01% | -89.0% |
| Q2 2023 | $37,547,725 | -36.6% | 798,548 | -43.4% | 0.07% | -42.1% |
| Q1 2023 | $59,244,540 | +66.5% | 1,411,929 | +51.3% | 0.13% | +57.5% |
| Q4 2022 | $35,581,683 | -9.4% | 932,923 | -7.0% | 0.08% | -7.0% |
| Q3 2022 | $39,264,000 | -24.7% | 1,002,660 | -37.9% | 0.09% | -19.6% |
| Q2 2022 | $52,175,000 | +148.6% | 1,615,306 | +154.8% | 0.11% | +167.5% |
| Q1 2022 | $20,986,000 | +1334.4% | 634,033 | +1743.8% | 0.04% | +1233.3% |
| Q4 2021 | $1,463,000 | -58.3% | 34,387 | -56.6% | 0.00% | -80.0% |
| Q3 2021 | $3,510,000 | +875.0% | 79,221 | +1806.2% | 0.02% | +650.0% |
| Q4 2020 | $360,000 | -50.2% | 4,156 | -64.9% | 0.00% | -60.0% |
| Q3 2020 | $723,000 | -5.5% | 11,827 | -55.6% | 0.01% | -37.5% |
| Q1 2020 | $765,000 | +15.9% | 26,651 | +191.7% | 0.01% | +60.0% |
| Q4 2019 | $660,000 | +104.3% | 9,136 | +296.9% | 0.01% | +66.7% |
| Q3 2019 | $323,000 | -66.7% | 2,302 | -56.5% | 0.00% | -62.5% |
| Q2 2019 | $970,000 | -86.7% | 5,296 | -88.4% | 0.01% | -76.5% |
| Q1 2019 | $7,266,000 | +1.8% | 45,690 | -38.7% | 0.03% | -53.4% |
| Q4 2018 | $7,141,000 | -62.4% | 74,548 | -44.5% | 0.07% | -9.9% |
| Q3 2018 | $18,978,000 | +34.7% | 134,352 | +49.3% | 0.08% | -61.6% |
| Q2 2018 | $14,086,000 | -54.3% | 89,990 | -53.0% | 0.21% | -83.5% |
| Q1 2018 | $30,828,000 | +38.9% | 191,397 | +42.0% | 1.28% | +37.0% |
| Q4 2017 | $22,201,000 | +1454.7% | 134,788 | +570.3% | 0.93% | +1252.2% |
| Q1 2017 | $1,428,000 | -91.0% | 20,108 | -93.5% | 0.07% | -33.7% |
| Q4 2016 | $15,833,000 | -49.0% | 310,087 | -54.0% | 0.10% | -52.9% |
| Q3 2016 | $31,017,000 | +49.0% | 673,539 | -2.5% | 0.22% | +26.3% |
| Q2 2016 | $20,818,000 | +996.3% | 690,965 | +1066.7% | 0.18% | +872.2% |
| Q1 2016 | $1,899,000 | +1.6% | 59,222 | +84.6% | 0.02% | 0.0% |
| Q4 2015 | $1,870,000 | – | 32,074 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |